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Abstract
Introduction and hypothesis This study aims to compare
the surgical outcomes between hysterectomy and uterine
preservation in pelvic reconstruction with Perigee® and
Apogee® systems for severe pelvic organ prolapse.
Methods Ninety-one women who have undergone trans-
vaginal pelvic reconstructive surgery with Perigee and
Apogeesystemsforseverepelvicorganprolapseweredivided
into two groups: hysterectomy (n=39) and uterine preserva-
tion (n=52). The pre-operative and post-operative assess-
ments include subjective urinary and prolapse symptoms,
objective pelvic organ prolapse quantification (POP-Q)
system, urodynamic examination, and complications.
Results The mean follow-up period was 8.9 months (range,
0.9–26.5). There were no anatomical differences between
the two groups other than a longer perineal body in the
hysterectomy group (3.9 vs. 3.6, p<0.05) and a longer total
vaginal length in the uterine preservation group (8.2 vs. 7.8,
p<0.05). Preservation of uterus has significantly reduced
operative time, blood loss, and days of urine indwelling
catheter (p<0.001).
Conclusions Hysterectomy and uterine preservation have
comparable anatomical outcomes and post-operative com-
plications in pelvic reconstruction with Perigee and Apogee
systems at short-term follow-up.
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It has been estimated that approximately 50% of parous
women suffer from pelvic organ prolapse (POP) and 11% of
all women up to the age of 80 years will have surgery for
POP or urinary incontinence, with a reoperation rate of
29% [1, 2]. The success observed with the use of mesh in
general surgery, combined with the high failure rates for
traditional colporrhaphy, have led to new surgical
approaches and reconstructive materials in gynecologic
reconstructive surgery. In 2004, the Food and Drug
Administration approved the use of commercial kits that
delivered polypropylene mesh through a transvaginal
technique. Commercial graft kits have been developed in
response to high prolapse recurrence rates and desire for
minimally invasive, time-efficient procedures. Perigee/
Apogee® (American Medical Systems, Minnetoka, MN,
USA) is one of such kits applied for the pelvic reconstruc-
tion of the anterior, middle, and posterior compartments
defects. This can be achieved in patients without a uterus,
or the mesh can be used to re-suspend a retained uterus.
For correction of POP, hysterectomy is considered as a
standard practice even though descent of the uterus is a
consequence and not the cause of prolapse [3]. Will
hysterectomy help or hinder our efforts to achieve a
successful and long lasting anatomical result for woman
with POP? The answer to this question is still under debate
and needs to be considered from both patient and physician
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DOI 10.1007/s00192-011-1513-1perspectives. Few studies on uterine preservation have been
reported, and there are no clear indications for uterus
sparing or removal in open or vaginal surgery for advanced
prolapse [4–6]. Because uterine preservation or not with
both Perigee and Apogee have not been directly compared
in the literature, the appropriate management of a patient
scheduled for Perigee and Apogee with a uterus in situ
remains unclear. In this study, we performed both Perigee
and Apogee in women with advanced POP and compared
the peri- and post-operative outcomes between groups of
uterine preservation and hysterectomy.
Materials and methods
From May 2008 to September 2010, 123 consecutive
patients with symptomatic POP quantification (POP-Q)
system stage III–IV, who underwent transvaginal pelvic
reconstructive surgery with Perigee and Apogee systems at
our hospital were recruited [7]. Three patients were excluded
because of missing POP-Q records and another 29 patients
were excluded as well for previous hysterectomy history with
vault prolapse. The remaining 91 women with uterus in situ
were divided into the hysterectomy group (n=39) and the
uterine preservation group (n=52).
Patients had been interviewed to identify urinary and
prolapse symptoms. The POP-Q standard scoring system
and the 3×3 grid system were adopted for staging and
recording the nine points of the POP-Q system. Pre-
operative POP-Q values and stages were measured under
anesthesia in operative room while post-operative POP-Q
values and stages were measured at each clinical follow-up.
All POP-Q points were measured by the corresponding
author (K.-H. Huang). Baseline demographic data including
age, body mass index, obstetric and gynecologic history,
and medical and surgical history were obtained. The
following pre-operative and peri-operative information
were also collected: urinalysis taken 18–24 h prior to
surgery, hemoglobin taken 18–24 h before and after surgery,
operative time (from skin incision to skin closure),
estimated blood loss, days of urine indwelling catheter,
length of stay in hospital recorded in days, and peri-
operative complications. All the women without post-
menopausal bleeding, previous cervical intraepithelial neo-
plasia (CIN), abnormal cervical smears, or uterine diseases
were offered the option to preserve the uterus.
All patients have undergone pre-operative multichannel
urodynamic studies with prolapse reduction to determine
whether there was any evidence of urodynamic stress
incontinence or occult stress urinary incontinence. Those with
confirmed urodynamic stress incontinence had placement of a
transvaginal midurethral polypropylene sling (Transobturator
tape (TOT®), American Medical Systems, Minnetoka, MN,
USA) at the same time. Cystoscopy was performed on all
patients after mesh was placed intraoperatively to exclude any
bladder injury and to confirm intact ureters.
All cases were performed by a single surgeon (Dr. K.-H.
H.) using the technique outlined by the manufacturer with
only subtle differences in the Apogee procedure involved
[8]. Dr. K.-H. H. passed the needle through the sacrospi-
nous ligament at a level of 2 cm posterior and medial to the
ischial spine rather than the ileococcygeus muscle at the
level of the ischial spine. All patients were given antibiotic
prophylaxis (intravenous Cefazolin 1 gm; Chi-Sheng
Chemical Co., Hsinchu, Taiwan) administered 30 min
before surgery and till 2 to 3 days (intravenous Cefazolin
1 gm every 8 h) after surgery. General anesthesia was
applied in all operations.
Post-operative follow-up was scheduled at 1, 3, 6, and
12 months and then annually. Primary post-operative data
consisted of POP-Q values, stage of prolapse, and compli-
cations. Urinary symptoms of complication included dysuria,
urine retention, confirmed urinary tract infection, nocturia,
frequency, urgency, urgent incontinence, and stress inconti-
nence using the 2002ICS definitions [9]. Abnormal sensation
was defined as groin, vaginal, buttock, or thigh pain;
numbness; or weakness. Mesh extrusion was confirmed by
pelvic examination. Symptoms or signs which did not fit
descriptions above were classified under the category of
other complication. Recurrence was defined as most distal
portion of POP stage II or greater.
Charts were reviewed by computerized hospital records.
Data were collected and reviewed by the first author. Ethical
approvalbytheInstitutionalReviewBoardofourhospitalhad
been obtained for retrospective data analysis. Continuous
variables were summarized with means and standard devia-
tions and were compared between groups using Student’s t
test. Categorical variables were summarized with counts and
percents and were compared between groups using chi-
square test with Fisher’s exact test, if necessary. The change
from pre- to post-operative status for POP-Q values was
assessed using paired Student’s t tests. A difference was
considered statistically significant when p<0.05.
Results
Comparison of baseline characteristic between the two
groups: hysterectomy and uterine preservation are listed in
Table 1. No significant differences between the two groups
were identified, except for the uterine preservation group had
older age (65.5 vs 59.3; p=0.003), higher parity (3.9 vs 3.3;
p=0.02), and more patients with menopause (98.1% vs
66.7%;p<0.001). The mean follow-up period was 8.9 months
(range, 0.9–26.5). There was no significant difference of the
follow-up time between the two groups (p=0.249).
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pre-operative and post-operative POP-Q values and the
stage of prolapse between the hysterectomy and uterine
preservation groups are summarized in Tables 2 and 3,
respectively. All the parameters of POP-Q values (Aa, Ba, C,
Ap, Bp, genital hiatus, perinealbody, and total vaginal length)
and stages have significant improvements (p<0.001) in both
groups after surgery except for total vaginal length in the
hysterectomy group (p=0.815; Table 2). Post-operative POP-
Q values and stages between the two groups did not differ
significantly (p>0.05; Tables 2 and 3) except for perineal
body (hysterectomy, 3.9; uterine preservation, 3.6; p=0.032)
and total vaginal length (hysterectomy, 7.8; uterine preser-
vation, 8.2; p=0.04; Table 2).
Peri-operative outcomes were compared between the two
surgical groups and are summarized in Table 4. Operative
time (129.3 vs 97.2; p<0.001), estimated blood loss (179.5
vs 77.4; p<0.001), and days of urine indwelling catheter
(2.7 vs 2.4; p=0.006) of the hysterectomy group were
significantly higher than those in the uterine preservation
group. There was no significant difference between the two
groups inpost-operativehemoglobin(11.1 vs11.4,p=0.370),
hospital stay (5.3 vs 4.9; p=0.103), and complications,
including urinary symptoms, abnormal sensation, or symp-
Table 1 Baseline characteristics in both groups
Variable Hysterectomy (n=39) Uterine preservation (n=52) P value
Age (years) 59.3±10.7 65.5±8.0 0.003
a*
Parity 3.3±1.4 3.9±1.1 0.020
a*
BMI (kg/m
2) 25.3±2.4 24.9±3.4 0.600
a
Menopause 26 (66.7) 51 (98.1) <0.001
b*
Diabetes Mellitus 11 (28.2) 9 (17.3) 0.306
b
Hypertension 14 (35.9) 25 (48.1) 0.288
b
History of POP repair 1 (2.6) 2 (3.8) =0.99
b
Concomitant transobturator tape (TOT) 24 (61.5) 35 (67.3) 0.659
b
Pre-operative hemoglobin (gm/dL) 13.0±1.4 12.9±1.2 0.737
a
Pre-operative urinalysis (positive) 10 (25.6) 15 (28.8) 0.815
b
Follow-up time (months) 7.9±5.3 9.4±7.2 0.249
a
Data are given as mean±standard deviation, or n (%)
BMI body mass index, POP pelvic organ prolapse
aStudent’s t test
bChi-square test with Fisher’s exact test
*p<0.05, statistically significant
Table 2 Pre-operative and post-operative pelvic organ prolapse quantification (POP-Q) values in both groups
POP-Q variables (cm) Hysterectomy (n=39) Uterine preservation (n=52) Post-op p value
a
Pre-op Post-op p Value
a Pre-op Post-op p Value
a
Aa +2.9±0.3 −3.0±0.0 <0.001* +2.9±0.3 −3.0±0.2 <0.001* 0.159
Ba +4.8±1.2 −3.2±0.9 <0.001* +4.6±1.1 −3.1±0.6 <0.001* 0.352
C +4.4±1.8 −7.6±0.9 <0.001* +4.0±1.7 −7.7±0.9 <0.001* 0.582
Ap +2.7±0.7 −3.0±0.0 <0.001* +2.4±0.7 −3.0±0.0 <0.001* =0.99
Bp +3.7±1.5 −3.1±0.8 <0.001* +3.0±1.4 −3.1±0.7 <0.001* 0.839
Gh 4.8±0.9 3.7±0.9 <0.001* 5.0±0.7 3.6±0.8 <0.001* 0.666
Pb 3.2±0.6 3.9±0.4 <0.001* 3.0±0.6 3.6±0.7 <0.001* 0.032*
tvl 7.7±1.2 7.8±1.0 0.815 7.5±0.9 8.2±0.8 <0.001* 0.040*
Data are given as mean±standard deviation
Pre-op pre-operative, Post-op post-operative, gh genital hiatus, pb perineal body, tvl total vaginal length
aStudent’s t test
*p<0.05, statistically significant
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symptoms or abnormal sensation (p>0.05).
Secondary outcome analyses showed that there was no
significant differences between the two groups for mesh
extrusion (hysterectomy, 12.8%; uterine preservation, 3.8%;
p=0.134), urinary symptoms (hysterectomy, 30.8%; uterine
preservation, 44.2%; p=0.276), abnormal sensation (hys-
terectomy, 7.7%; uterine preservation, 5.8%; p=0.99), and
other post-operative complications (hysterectomy, 17.9%,
uterine preservation, 7.7%; p=0.195; Table 5). There was
no major peri-operative complication except for one blood
transfusion with two units of packed RBC in the hysterec-
tomy group, and no rectum or bladder perforation during
operation in both groups.
There was an approximately 98% anatomical cure rate
(hysterectomy, 39 out of 39, 100%; uterine preservation, 50
out of 52, 96%; at POP-Q stage I or less) of severe pelvic
Discussion
Concomitant hysterectomy or uterine preservation of
vaginal mesh surgeries for pelvic organ prolapse are still
under debate and have not been adequately addressed in the
literature. There are several case series describing results
after use of vaginal mesh; however, most of these studies
combine the outcomes of Perigee and/or Apogee, Prolift®
(Women’s Health and Urology⁄Ethicon, Somerville, NJ,
USA) insertions and do not stratify according to hysterec-
tomy versus uterine preservation [10, 11]. There was a
study investigated the outcomes related to total Prolift with
and without leaving the uterus in situ [12]. But the
comparison of outcomes related to Perigee and Apogee
with and without hysterectomy has not been adequately
addressed. This study attempted to assess the differences
between using Perigee and Apogee with and without
hysterectomy.
All the women without post-menopausal bleeding,
previous CIN, abnormal cervical smears, or uterine disease
Table 3 Pre-operative and post-operative pelvic organ prolapse quantification (POP-Q) stages in both groups
POP-Q stage Hysterectomy (n=39) Uterine preservation (n=52) Post-op p value
a
Vaginal wall Pre-op Post-op p Value
a Pre-op Post-op p Value
a
Anterior 3.9±0.3 0.9±0.2 <0.001* 3.9±0.3 1.0±0.1 <0.001* 0.402
Apex 3.7±0.7 0.0±0.0 <0.001* 3.6±0.7 0.0±0.0 <0.001* =0.99
Posterior 3.5±0.6 1.0±0.2 <0.001* 3.2±0.6 1.0±0.1 <0.001* 0.839
Data are given as mean±standard deviation
aStudent’s t test
*p<0.05, statistically significant
Table 4 Peri-operative outcomes
Variable Hysterectomy (n=39) Uterine preservation (n=52) p Value
Operative time (min) 129.3±27.5 97.2±19.2 <0.001
a*
Estimated blood loss (ml) 179.5±127.1 77.4±42.9 <0.001
a*
Post-operative hemoglobin (gm/dL) 11.1±1.4 11.4±1.0 0.370
a
Duration of urine indwelling catheter (days) 2.7±0.5 2.4±0.5 0.006
a*
Hospital stay (days) 5.3±1.0 4.9±1.1 0.103
a
Complications
None 35 (89.7) 43 (82.7) 0.383
b
Urinary symptoms 2 (5.1) 7 (13.5) 0.291
b
Abnormal sensation 1 (2.6) 1 (1.9) =0.99
b
Other 1 (2.6) 1 (1.9) =0.99
b
Data are given as mean±standard deviation, or n (%)
aStudent’s t test
bChi-square test with Fisher’s exact test
*p<0.05, statistically significant
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organ prolapse. Two recurrent cystocele POP-Q stage II was
both noted in uterine preservation group 7 and 10 months
after surgery, respectively.were offered the chance to preserve the uterus. In this study,
the hysterectomy group had significantly younger age, less
parity, and fewer patients with menopause. By reviewing
the charts, we found that more patients with uterine
myomas or menstrual discomforts such as dysmenorrhea
and menorrhagia were noted in the hysterectomy group (23
out of 39). Most of these symptomatic patients who
received hysterectomy were in reproductive age. This could
explain the causes of younger age, less parity, and less
patients with menopause in the hysterectomy group.
Our study also showed that POP-Q values and the stage
of prolapse significantly improved after both surgeries, and
there were no significant differences in post-operative POP-
Q values and stages in any vaginal compartment of both
groups. This might suggest that either hysterectomy or
uterine preservation group has similar anatomical outcomes
in pelvic reconstruction for severe pelvic organ prolapse at
short-term follow-up. However, less elongation of total
vaginal length after surgery was noted in the hysterectomy
group. That is probably because of partial vaginal wall was
cut along with the uterine cervix during procedure of
hysterectomy. Longitudinal suturing of vaginal cuff after
removal of uterus might increase the vaginal length.
There was no significant difference between the two
groups in peri-operative outcomes and post-operative
complications except that the uterine preservation group
has significantly reduced operative time, estimated blood
loss, and days of urine indwelling catheter. This indicated
that both hysterectomy and uterine preservation groups are
equally safe but the uterine preservation group had the
advantage of shorter operative time, reduced estimated
blood loss, and fewer days of urine indwelling catheter.
Hysterectomy may result in damage to the nerve supply or
supportive tissues of the pelvic floor, which may lead to
subsequent pelvic floor dysfunction and cause longer days
of urine indwelling catheter post-operatively. Though the
days of an indwelling catheter of 2.7 vs. 2.4 days seem not
to be clinically important, there is still 0.3 day=7.2 h
difference between the two groups. We think patients may
have more discomforts with a longer duration of 7.2 h of
urine indwelling catheter. But this is a priori without
subjective questionnaires. If the longer duration of urine
indwelling catheter increased the infection rate also remains
unclear without post-operative urinalysis or urine culture.
We would collect more subjective and objective data to
clarify the impact of duration of urine indwelling catheter
on clinical condition in future studies. Furthermore, the
average hospital stay was about 5 days in our study for a
vaginal surgery. This is far more than the average stay in
most western countries (less than 1 day in the USA and
Canada). The discrepancy is probably because of the
convenient and affordable medical treatment in Taiwan
and cultural difference. The rate of doctor visits and
hospitalizations is higher than in most western countries
since the Taiwan’s national health insurance started in 1995
(information on the Web site of Bureau of National Health
Insurance http://www.nhi.gov.tw/english/index.aspx). Each
patient in our study only had to pay average 300 USD for
her hospitalization and surgery (not including the materials
expenses of Perigee and Apogee about 2,000 USD).
Recently, concern over complications with vaginal mesh
hasbeenraised.Complicationsthatmayberelatedtothemesh
itself, such as mesh vaginal extrusion, pain (vaginal, groin,
buttock, or leg), dyspareunia, infection, or fistula, have been
reported in the literature [13, 14]. The rate of mesh extrusion
in this study is consistent with other published reports of
type I mesh complications at 3% to 12% [15, 16]. In the
present study, the rate of mesh extrusion was higher in the
hysterectomy group (hysterectomy, 12.8%; uterine preserva-
tion, 3.8%) but was not statistically significant (p=0.134;
Table 5). Collinet et al. proposed that uterine preservation is a
protective factor of mesh extrusion and reported an increased
hysterectomy in the past [14]. The clinically significant
mesh extrusion difference in our study correlated with this
observation. Besides, more complications seemed to have
been noted at clinical follow-up, but follow-up beyond
12 months could therefore reveal more significant differences
between the two groups and between the peri-operative and
post-operative periods for complications.
Should we expect uterine preservation to be better than
hysterectomy in pelvic reconstruction for pelvic organ
prolapse—and could it become the surgical gold standard in
the future? It might be too early to draw any definite
conclusions. In this study, we have brought up an alternative
procedure in pelvic reconstruction for severe pelvic organ
prolapse: the uterine preservation which is potentially
Variable Hysterectomy (n=39) Uterine preservation (n=52) p Value
a
None 12 (30.8) 20 (38.5) 0.510
Mesh extrusion 5 (12.8) 2 (3.8) 0.134
Urinary symptoms 12 (30.8) 23 (44.2) 0.276
Abnormal sensation 3 (7.7) 3 (5.8) =0.99
Other 7 (17.9) 4 (7.7) 0.195
Table 5 Post-operative
complications
Data are given as n (%)
aChi-square test with Fisher’s
exact test
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relative risk of 5.16 compared with the situation when the
uterus was preserved or when the patient had had aeffective and minimally invasive. We offered choices and let
patients know that hysterectomy was not the only option.
A weakness of the study was that we did not collect data
regarding the subjective outcomes of patients and quality of
lifeusingstandardizedquestionnaireaftertheprocedure.Post-
operative multichannel urodynamic studies were not obtained
completely to compare the change from preoperative to post-
operative conditions.Otherlimitationsofourstudyareshorter
follow-up of anatomical and functional results, and non-
prospective randomized trials. A further study that focuses on
the prospective collection of data controlling for baseline
characteristics at the time of enrolment, randomizing patients
to either hysterectomy or uterine preservation and having
follow-up beyond 12 months or longer should be done.
In conclusion, there were no significant differences
between the hysterectomy group and the uterine preserva-
tion group for post-operative POP-Q values and stages and
post-operative complications in pelvic reconstruction with
Perigee and Apogee systems for severe pelvic organ
prolapse after an average of 8.9 months of follow-up
(range, 0.9–26.5). The notable differences between the two
procedures were a longer perineal body after hysterectomy
and a longer total vaginal length after uterine preservation.
Preservation of uterus has the significant advantage of
shorter operative time, less blood loss, and fewer days of
urine indwelling catheter. Longer follow-up of anatomical
and functional results are needed.
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